Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novartis Ireland Limited .
Filed returns
70
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Novartis Ireland Limited | Health | National Cardiovascular Health Strategy (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Health System Readiness for Advanced Cancer Therapy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) | 27 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Life Science Strategy (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | IIEA event on EU Presidency and Public Health (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | European Presidency plans for Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Attended an event for World Cancer Day (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Foreign Affairs | Policy Agenda for the EU Presidency (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Supporting a Health Policy Partnership Initiative for them to run a roundtable and draft a white paper with policy stakeholders. (Public policy or programme) | 26 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Roundtable policy meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Implementation of the decision to include SMA in newborn screening (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Forwarding letter to Dept of Health about access to innovative treatment for Irish patients (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Invitation to a meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Environment | Meeting with Department of Environment officials about the EU Mercury Committee (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | American Chamber of Commerce Event (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | AI4Ireland meeting with Oireachtas members (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | World Urticaria Day event (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Invited to the Joint Oireachtas All Party Committee on Orphan Drugs (3/12/25) (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Advocate for Life Science Strategy (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Implement the decision to include SMA screening implemented in the heelprick test for newborn babies (Matters involving public funds) | 0 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Environment | EU Mercury Committee (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Launch of the Rare Disease National Strategy at Department of Health (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Letter to Tanaiste about access to innovative treatment for Irish patients (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Justice and Equality | IIEA Meeting with Minister for Justice (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | IIEA event with a panel of speakers about Developing a National Life Sciences Vision for Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Rare Disease Ireland invite to Leinster House (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | EU Affairs | Attending a meeting organised by Hanover with the Minister for EU Affairs (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Foreign Affairs | EU Presidency (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Implementation of SMA onto the Heel prick test (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Timely inclusion of SMA in heel prick test (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Rare diseases conference, as an official event of the Irish EU Presidency (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | IPHA Industry meeting - engagement on trade and tariff issues (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Timely inclusion of SMA in heal prick test (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Competitivness, government needs to be perceived as pro-innovation (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Life Sciences strategy for Ireland (Public policy or programme) | 9 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Implementation of SMA testing into the heel prick test for newborns (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | To fund an Office of Life Sciences or Life Science Strategy (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 25 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Environment | Urban waste water directive (Legislation) | 2 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Access in Heart Failure (HF) & healthcare system readiness for new medicine platforms like radioligand therapies. Clinical trial attractiveness (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 6 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Ensure that the healthcare system is ready for new novel treatments like radioligand therapies. Also employing guideline-directed therapy for heart failure patients. (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Environment | EU Mercury Committee to approve a process which is a more efficient use of scarce raw materials (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2023 | Novartis Ireland Limited | Health | Budget for innovative new medicines in 2024 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2023 | Novartis Ireland Limited | Health | Expansion of newborn screening in Ireland (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2023 | Novartis Ireland Limited | Health | Ensuring the spinal muscular atrophy (SMA) is added to the heel prick test in a timely manner (Matters involving public funds) | 11 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Concerns over Europe’s competitiveness and pro-innovation environment, regarding the revision of the EU pharmaceutical Legislation (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Expension of the newborn screening program - adding more diseases to the heel prick test (Matters involving public funds) | 3 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 62 | 88.6% | |
| Environment | 4 | 5.7% | |
| Foreign Affairs | 2 | 2.9% | |
| EU Affairs | 1 | 1.4% | |
| Justice and Equality | 1 | 1.4% |